Shao F - Search Results

1

Pharmacokinetics, Tolerability, Safety, and Immunogenicity of LY01008 and Bevacizumab (Avastin®) in Healthy Chinese Subjects.

Xie L, Zhu Y, Liang Z, Zhao Y, Zhou S, Chen J, Zhang H, Ding S, Wang L, Shao F. Xie L, et al. Among authors: shao f. Eur J Drug Metab Pharmacokinet. 2022 May;47(3):309-317. doi: 10.1007/s13318-021-00752-7. Epub 2022 Feb 3. Eur J Drug Metab Pharmacokinet. 2022. PMID: 35112328 Clinical Trial.

2

Pharmacokinetics of ginkgolides A, B and K after single and multiple intravenous infusions and their interactions with midazolam in healthy Chinese male subjects.

Shao F, Zhang H, Xie L, Chen J, Zhou S, Zhang J, Lv J, Hao W, Ma Y, Liu Y, Ou N, Xiao W. Shao F, et al. Eur J Clin Pharmacol. 2017 May;73(5):537-546. doi: 10.1007/s00228-017-2197-3. Epub 2017 Jan 20. Eur J Clin Pharmacol. 2017. PMID: 28105513 Clinical Trial.

3

A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [¹⁴C]fruquintinib, a novel oral selective VEGFR inhibitor, in healthy Chinese male volunteers.

Zhou S, Shao F, Xu Z, Wang L, Jin K, Xie L, Chen J, Liu Y, Zhang H, Ou N. Zhou S, et al. Among authors: shao f. Cancer Chemother Pharmacol. 2017 Sep;80(3):563-573. doi: 10.1007/s00280-017-3394-6. Epub 2017 Jul 20. Cancer Chemother Pharmacol. 2017. PMID: 28730290 Clinical Trial.

4

Effects of CYP3A4*1G and CYP3A5*3 polymorphisms on pharmacokinetics of tylerdipine hydrochloride in healthy Chinese subjects.

Zhou S, Tao M, Wang Y, Wang L, Xie L, Chen J, Zhao Y, Liu Y, Zhang H, Ou N, Wang G, Shao F, Aa J. Zhou S, et al. Among authors: shao f. Xenobiotica. 2019 Mar;49(3):375-380. doi: 10.1080/00498254.2018.1447711. Epub 2018 Mar 28. Xenobiotica. 2019. PMID: 29521134 Clinical Trial.

5

Development and validation of two LC-MS/MS methods to assay urinary tylerdipine hydrochloride and its metabolites in healthy Chinese subjects.

Tao M, Zhou S, Wang Y, Wang L, Zhao Y, Xie L, Chen J, Liu Y, Zhang H, Ou N, Wang G, Shao F, Aa J. Tao M, et al. Among authors: shao f. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Oct 1;1096:172-179. doi: 10.1016/j.jchromb.2018.08.017. Epub 2018 Aug 21. J Chromatogr B Analyt Technol Biomed Life Sci. 2018. PMID: 30176506

6

A Randomized, Open-Label, Crossover Phase 1 Study to Evaluate the Effects of Food on the Pharmacokinetics of a Single Oral Dose of a 15-mg Tylerdipine Tablet in Healthy Chinese Male Volunteers.

Wang L, Xie L, Zhou S, Wang Y, Chen J, Zhou Y, Liu Y, Zhang H, Tao M, Ou N, Shao F. Wang L, et al. Among authors: shao f. Clin Pharmacol Drug Dev. 2019 Jan;8(1):126-132. doi: 10.1002/cpdd.622. Epub 2018 Oct 10. Clin Pharmacol Drug Dev. 2019. PMID: 30303628 Clinical Trial.

7

Pharmacokinetics, Safety and Tolerability of Tylerdipine Hydrochloride, a Novel Dihydropyridine Dual L/T-type Calcium Channel Blocker, after Single and Multiple Oral Doses in Healthy Chinese Subjects.

Zhou S, Wang Y, Wang L, Xie L, Chen J, Liu Y, Zhang H, Zhao Y, Ou N, Shao F. Zhou S, et al. Among authors: shao f. Clin Drug Investig. 2019 Jan;39(1):85-96. doi: 10.1007/s40261-018-0722-5. Clin Drug Investig. 2019. PMID: 30368658 Clinical Trial.

8

Bioequivalence Study of 2 Formulations of Rivaroxaban, a Narrow-Therapeutic-Index Drug, in Healthy Chinese Subjects Under Fasting and Fed Conditions.

Ding S, Wang L, Xie L, Zhou S, Chen J, Zhao Y, Deng W, Liu Y, Zhang H, Shao F. Ding S, et al. Among authors: shao f. Clin Pharmacol Drug Dev. 2020 Apr;9(3):346-352. doi: 10.1002/cpdd.742. Epub 2019 Oct 14. Clin Pharmacol Drug Dev. 2020. PMID: 31610099 Clinical Trial.

9

Metabolic disposition of [¹⁴ C]-abivertinib, an epidermal growth factor receptor tyrosine kinase inhibitor: Role of glutathione conjugation.

Wang L, Guo L, Wang Y, Guo R, Xu Z, Gao Z, Xie L, Chen J, Chen Y, Liu Y, Zhang H, Bao L, Xu W, Zhu M, Shao F, Shu Y. Wang L, et al. Among authors: shao f. Br J Clin Pharmacol. 2021 Mar;87(3):1475-1485. doi: 10.1111/bcp.14555. Epub 2020 Nov 5. Br J Clin Pharmacol. 2021. PMID: 32959915 Free article.

10

Mass balance, metabolic disposition, and pharmacokinetics of [¹⁴C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration.

Zhou S, Liu W, Zhou C, Zhang L, Xie L, Xu Z, Wang L, Zhao Y, Guo L, Chen J, Ding L, Mao L, Tao Y, Zhang C, Ding S, Shao F. Zhou S, et al. Among authors: shao f. Cancer Chemother Pharmacol. 2020 Dec;86(6):719-730. doi: 10.1007/s00280-020-04159-0. Epub 2020 Oct 12. Cancer Chemother Pharmacol. 2020. PMID: 33044566 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,237 results

Search Page